Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Pre Neoplastic High Grade HPV-related Vulvar and Cervical Lesions
NCT04211103Phase 2Unknown
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2020
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in cervical squamous intraepithelial lesion (SIL) and vulvar intraepithelial neoplasia (VIN), sponsored by Policlinico Gemelli. Primary endpoint: Proportion of subjects with no evidence of cervical HSIL on histology at surgical treatment at 18 months. Status: unknown.
02
Drugs
03
Conditions
cervical squamous intraepithelial lesion (SIL)vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on NCT04211103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04211103.